Regular Article
Xenogeneic DNA Immunization in Melanoma Models for Minimal Residual Disease

https://doi.org/10.1006/jsre.2001.6302Get rights and content

Abstract

Introduction. DNA immunization with xenogeneic genes encoding homologous antigens protects mice against tumor challenge with syngeneic melanoma in a lung metastasis model. The effect of xenogeneic human TRP-2 (hTRP2) DNA immunization on disease confined to an orthotopic site, the skin, and in a model of minimal residual disease that is relevant to a setting of adjuvant therapy for micrometastatic cancer is reported.

Methods. Immunization and tumor challenge with B16F10LM3 melanoma were performed in C57BL/6 mice and in mice genetically deficient in MHC class I or II molecules. A melanoma variant of B16 with a predilection for lung metastasis was selected and used to challenge C57BL/6 mice. Tumor challenge in the footpad with the B16 variant was followed by local tumor growth and lung metastasis. The tumor-bearing distal extremities were surgically resected and mice were randomized to receive hTRP2 DNA immunization or no treatment. Approximately 3–5 weeks after surgical resection, lungs were harvested and metastases counted.

Results. Xenogeneic DNA immunization with hTRP2 prevented tumor growth in the skin by a mechanism requiring CD4+ and CD8+ T cells but did not inhibit the growth of established tumors. Adjuvant immunization with hTRP2 DNA after resection significantly reduced lung metastases and decreased local recurrence rates after surgical resection.

Conclusions. Xenogeneic DNA immunization with hTRP2 was effective in protecting mice from intradermal tumor challenge. Immunization prevented local recurrence and the development of metastases in a mouse model of minimal residual disease, supporting a role for DNA immunization against melanosomal antigens as an adjuvant to surgery in high-risk primary melanomas.

References (11)

  • W.G. Hawkins et al.

    Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity

    Surgery

    (2000)
  • L.W. Weber et al.

    Tumor immunity and autoimmunity induced by immunization with homologous DNA

    J. Clin. Invest.

    (1998)
  • W.B. Bowne et al.

    Coupling and uncoupling of tumor immunity and autoimmunity

    J. Exp. Med.

    (1999)
  • R.J. North et al.

    T cell-mediated suppression of the concomitant antitumor immune response as an example of transplantation tolerance

    Transplant. Proc.

    (1984)
  • W.B. Bowne et al.

    Injection of DNA encoding granulocyte–macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects

    Cytokines Cell. Mol. Ther.

    (1999)
There are more references available in the full text version of this article.

Cited by (38)

  • Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice

    2011, Vaccine
    Citation Excerpt :

    Pre-clinical data indicate that trastuzumab resistance results from co-expression of growth factor receptors (EGFR family, IGF-1 R) and activation of the PI3K-Akt pathway (mainly by loss of PTEN function) [4]. We have previously made use of direct immunization with xenogeneic DNA vaccines in animal models of cancer [5–7]. Xenogeneic DNA vaccines have shown efficacy in pre-clinical mouse studies.

  • Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen

    2009, Vaccine
    Citation Excerpt :

    Recently xenogeneic antigens administered as DNA vaccine intramuscular were found to induce an immune response to melanoma in dogs [24]. Protection against murine glioma and melanoma was found after co-stimulation with xenogeneic but related antigens [25,26]. Following the xenogeneic approach epitope and antigen spreading [27] has been held responsible for the positive effect, however the precise mechanism and the relation between “target”antigen and adjuvant is less clear.

  • Xenovaccinotherapy for colorectal cancer

    2007, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    Although both autologous and allogeneic cell vaccines are well studied, we favor a xenogenic vaccine. Evidence has been accumulated to demonstrate that the xenogenic TAAs can be much more effective in eliciting antitumor immune responses than their homological analogs [5–9]. The vaccine under study is composed of disrupted murine B16 melanoma and LLC carcinoma cells.

  • Immunotherapy of Melanoma

    2006, Hematology/Oncology Clinics of North America
View all citing articles on Scopus

Abbreviation used: hTRP2, human-tyrosinase-related peptide-2.

View full text